← All trials
NCT00409305
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2007
- Primary completion
- —
- Completion date
- Jun 1, 2007
- First posted
- —
- Last posted
- —
- Enrollment
- 280
- Arms / groups
- — / —
- Source
- AACT · pre-existing
Sponsors
- OBEcure Ltd.Lead sponsor
- Radiant ResearchOverall official - principal investigator
- University of VermontOverall official - principal investigator
- Rochester Clinical ResearchOverall official - principal investigator
- L-Marc Research CenterOverall official - principal investigator
- Midwest Institute for Clinical ResearchOverall official - principal investigator
- Diablo Clinical ResearchOverall official - principal investigator
- Cahaba Research, IncOverall official - principal investigator
- University of CincinnatiOverall official - principal investigator
- Partners in HealthOverall official - principal investigator
- MRA Clinical ResearchOverall official - principal investigator
- National Center of Competence in Resaerch, SwitzerlandOverall official - principal investigator
- Indiana UniversityOverall official - principal investigator
- OBEcure Ltd.Study director
- OBEcure Ltd.Study chair
- CovanceOverall official - principal investigator
- Radiant ResearchStudy director
- ScrippsOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.